Pharmabiz

MHRA accepts Eisai's MAA for insomnia drug lemborexant for evaluation

MHRA accepts Eisai's MAA for insomnia drug lemborexant for evaluation: Tokyo Friday, July 3, 2026, 18:00 Hrs [IST] Eisai Co., Ltd., has announced that the United Kingdom’s (UK) ...
Pharmabiz

Roche announces positive result in Phase III trial of cancer drug divarasib

Roche announces positive result in Phase III trial of cancer drug divarasib: Basel Friday, July 3, 2026, 17:00 Hrs [IST] Roche announced positive results from the phase III Krasce ...
Pharmabiz

Vyome receives Chinese patent covering formulation and therapeutic use claims relating to its proprietary besifloxacin topical gel programme for inflammatory acne

Vyome receives Chinese patent covering formulation and therapeutic use claims relating to its proprietary besifloxacin topical gel programme for inflammatory acne: Cambridge, Mass ...
Pharmabiz

Artelo Biosciences presents positive new data from a preclinical study in neuropathic pain from spinal cord injury at ICRS 2026 annual symposium

Artelo Biosciences presents positive new data from a preclinical study in neuropathic pain from spinal cord injury at ICRS 2026 annual symposium: Solana Beach, California Friday, ...
Pharmabiz

Centre amends rules to ensure uniform regulation of advanced cell and gene therapies

Centre amends rules to ensure uniform regulation of advanced cell and gene therapies: Our Bureau, New Delhi Friday, July 3, 2026, 10:30 Hrs [IST] In a step to strengthen the regul ...
Pharmabiz

Novartis receives EC approval for Itvisma for SMA

Basel Friday, July 3, 2026, 15:00 Hrs [IST] Novartis has announced that the European Commission (EC) has approved Itvisma (onase ...
Pharmabiz

US FDA grants breakthrough therapy designation for INTENT Biologics’ PEP Biologic to treat diabetic foot ulcers

US FDA grants breakthrough therapy designation for INTENT Biologics’ PEP Biologic to treat diabetic foot ulcers: Rochester, Minnesota Friday, July 3, 2026, 09:00 Hrs [IST] INTEN ...
Pharmabiz

Samsung Bioepis in partnership with Harrow relaunches Byooviz in United States

Samsung Bioepis Co., Ltd. announced the relaunch of Byooviz (ranibizumab-nuna) in the United States (US), in partnership with Harrow. Harrow became responsible for commercialization of Byooviz ...
Pharmabiz

NITI Aayog launches report on strategic roadmap for making Ayurveda global

NITI Aayog released a report titled 'Strategic Roadmap for Making Ayurveda Global' with a comprehensive assessment of Ayurveda's global footprint and a phased roadmap for making Ayurveda global. The ...
Pharmabiz

Otsuka reports positive Phase 3 two-year eGFR results on Voyxact

Otsuka reports positive Phase 3 two-year eGFR results on Voyxact: Tokyo Friday, July 3, 2026, 16:00 Hrs [IST] Otsuka Pharmaceutical Co., Ltd., and Otsuka Pharmaceutical Developmen ...
Pharmabiz

Lupin receives EMA approval for change to the terms of marketing authorization for NaMuscla

Lupin receives EMA approval for change to the terms of marketing authorization for NaMuscla: Our Bureau, Mumbai Friday, July 3, 2026, 11:30 Hrs [IST] Global pharma major Lupin Lim ...
Pharmabiz

Agilent introduces AI-driven analysis module for Agilent xCELLigence RTCA eSight

Agilent introduces AI-driven analysis module for Agilent xCELLigence RTCA eSight: Santa Clara, California Friday, July 3, 2026, 12:00 Hrs [IST] Agilent Technologies Inc., a global ...